Orca Exploration: Graham-Style Deep Value Bargain

February 28, 2019 in Africa, Deep Value, Energy, Equities, Ideas, Micro Cap, Small Cap

This article is authored by Ideaweek participant Serge Belinski, chief executive officer of Value Holdings, based in Paris.

This write-up updates Serge’s in-depth presentation at Best Ideas 2018.

Orca Exploration Group is a holding company that trades below liquid assets. In addition, the company holds a stake in a valuable business worth multiples of the recent stock price (evidenced by a recent private market transaction).

Members, log in below to access the restricted content.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

Disclaimer: We are shareholders of Orca Exploration Group. The opinions expressed herein are our own and may contain errors. Our companies cannot be held liable for investment losses resulting from an investment that we recommended.

ZAGG: Smartphone Accessory Company at ~20% FCF Yield

February 26, 2019 in Equities, Ideas, Letters

This post is excerpted from a letter by MOI Global instructor Jim Roumell, partner and portfolio manager of Roumell Asset Management, based in Chevy Chase, Maryland.

ZAGG was created from the concept of applying a clear film originally designed to protect military helicopter blades in harsh desert conditions to protect consumers’ mobile devices. ZAGG designs, produces and distributes professional product solutions for mobile devices, including screen protection (glass and film), keyboards for tablet computers and mobile devices, keyboard cases, earbuds, mobile power solutions, cables, and cases under the ZAGG and InvisibleShield brands.

The company designs product solutions for users of mobile devices, and sells these products to consumers through global distribution partners and online. The company offers products for various market segments of handheld electronic devices, including smartphones, tablets, notebook computers, laptops, gaming devices, global positioning system (GPS) devices, watch faces, and similar devices and surfaces. Its other brands include mophie (power management and power cases) and BRAVEN (rugged Bluetooth audio). ZAGG has a #1 market share in screen protection (52%), #1 in battery cases (64%), #1 in external power and #2 in wireless charging (24%). Its products are distributed through big box retailers (e.g., Best Buy) and wireless carriers (e.g., AT&T), who like the higher margins of accessories.

ZAGG has made several acquisitions over the past few years. These acquisitions will move the company towards its stated revenue goal of $1 billion. For reference, revenue for 2018 and 2019 is estimated to be $535 million and $620 million, respectively. Management has stated that future acquisitions will be tuck-ins with revenue less than $50 million and also will be accretive within the year of acquisition.

One key acquisition was mophie. ZAGG acquired mophie in March 2016 for $62 million (adjusted for negative working capital). Integration was difficult. In 2017, ZAGG management replaced mophie’s entire senior management team. Additionally, mophie did not get certification from Apple to incorporate new wireless charging in its Power Cases until November of 2018, which caused a 60% decline in sales for that product. ZAGG management has confidence in the mophie division going forward.

A year ago, ZAGG’s stock price was over $21 per share. In addition to the questions surrounding mophie, the company faces competition at lower price points, particularly in screen protection, which represents about 60% of revenue. The share price also reacted to the news of a slowdown in iPhone sales. Of course, there is also a risk that smartphones of the future will not need screen protection, although that appears to be several years out if it occurs at all. Moreover, if this long-rumored prediction does occur, it’s likely to affect only higher-end, more expensive phones.

In the 4th quarter, we spoke with ZAGG CEO Chris Ahern. Mr. Ahern recently replaced the former CEO who retired. Mr. Ahern was the chief architect in turning around mophie as well as international sales. When speaking about M&A, he stated that ZAGG already has the infrastructure in place for $1 billion in sales. We believe Mr. Ahern has the right strategic vision for ZAGG. Management appears to be an astute capital allocator and has repurchased significant amounts of stock.

Members, log in below to access the restricted content.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

Disclosure: The specific securities identified and described do not represent all of the securities purchased, sold, or recommended for advisory clients, and the reader should not assume that investments in the securities identified and discussed were or will be profitable. The top three securities purchased in the quarter are based on the largest absolute dollar purchases made in the quarter.

Mark Walker on Why Investing Is Not as Hard as We Think

February 25, 2019 in Commentary, Curated, Equities, Featured, Full Video, Timeless Selections, Transcripts

MOI Global instructor Mark Walker, managing partner of Tollymore Investment Partners, spoke to students and alumni at the London Business School Value Investing Speaker Series in 2019.

Mark presented a context for investment managers to judge their prospects for success — a context that may allow investors to stay the course in periods of self-doubt. Mark discussed the behavioral constraints facing the investment management industry and some of the tactics and tools investors can employ to create long-term value.

Watch Mark’s talk:

Ben Claremon on Assessing Management

February 25, 2019 in Equities, Full Video, Idea Appraisal, Interviews, North America, Skills, Small Cap, Video Excerpt

MOI Global instructor Ben Claremon, principal and portfolio manager at Cove Street Capital, recently spoke to undergraduate value investing students at UCLA on the topic of assessing management and understanding the proxy statement. The students were pre-assigned Ben’s conversation with MOI Global to prepare for the class.

In 2014, we spoke with Ben on the importance and process of analyzing management’s business skill, capital allocation ability, and incentive alignment with shareholders.

Watch an excerpt of our interview with Ben, in which he discusses the significance of change-in-control provisions:

The full interview and Ben’s slide presentation at UCLA are available to members.

Members, log in below to access the restricted content.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

Miguel de Juan sobre ADL Bionatur

February 25, 2019 in Ideas de inversión, MOI Global en Español

NOTA DEL EDITOR: Esta idea de inversión es obtenida de una carta a los inversores de Argos Arca Global A.

* * *

Entre las nuevas empresas que hemos incorporado a la cartera se encuentra una empresa muy pequeñita, ADL Bionatur [BME: ADL], empresa perteneciente al MAB (Mercado Alternativo Bursátil) y que conocí gracias a un amigo, ¡gracias Alfredo!. Al ser tan pequeña y tan poco líquida la posición que tenemos en ella es muy pequeña, no alcanza el 1% del patrimonio del Argos. Algo que como sabéis no me suele gustar porque prefiero tener una cartera más concentrada. Posiblemente- depende siempre del precio- incrementemos algo más la posición en ella, pero nunca será una inversión significativa. Os la comento algo por encima.
Continue reading »

An Update on Our Investment in Ambac

February 22, 2019 in Letters

This article is authored by MOI Global instructor Phil Ordway, Managing Principal at Anabatic Investment Partners, based in Chicago, Illinois.

Ambac shares appreciated by 7.9% in 2018. The company reached two significant milestones in its restructuring by removing the segregated account from habilitation in January and exchanging its outstanding auction-market preferred shares for surplus notes in August. The situation in Puerto Rico also improved as the economy stabilized to a degree and an agreement was reached on Ambac’s sales-tax bond position.

The ongoing litigation with Countrywide/Bank of America remains a major unknown. In early January 2019 the judge in the case ruled in favor of Ambac on all six motions up for consideration. A trial date has been set for February 25, 2019, but it may get postponed due to appeals and settlement talks. A reassignment of the case to a new judge could impact the timing as well. If a settlement is not reached or a trial is not conducted during 2019 something has gone unexpectedly wrong.

Disclaimer: Gross Long and Gross Short performance attribution for the month and year-to-date periods is based on internal calculations of gross trading profits and losses (net of trading costs), excluding management fees/incentive allocation, borrowing costs or other fund expenses. Net Return for the month is based on the determination of the fund’s third-party administrator of month-end net asset value for the referenced time period, and is net of all such management fees/incentive allocation, borrowing costs and other fund expenses. Net Return presented above for periods longer than one month represents the geometric average of the monthly net returns during the applicable period, including the Net Return for the month referenced herein. An investor’s individual Net Return for the referenced time period(s) may differ based upon, among other things, date of investment. In the event of any discrepancy between the Net Return contained herein and the information on an investor’s monthly account statement, the information contained in such monthly account statement shall govern. All such calculations are unaudited and subject to further review and change. For purposes of the foregoing, the calculation of Exposure Value includes: (i) for equities, market value, and (ii) for equity options, delta-adjusted notional value.

THE INFORMATION PROVIDED HEREIN IS CONFIDENTIAL AND PROPRIETARY AND IS, AND WILL REMAIN AT ALL TIMES, THE PROPERTY OF ANABATIC INVESTMENT PARTNERS LLC, AS INVESTMENT MANAGER, AND/OR ITS AFFILIATES. THE INFORMATION IS BEING PROVIDED SOLELY TO THE RECIPIENT IN ITS CAPACITY AS AN INVESTOR IN THE FUNDS OR PRODUCTS REFERENCED HEREIN AND FOR INFORMATIONAL PURPOSES ONLY.

THE INFORMATION HEREIN IS NOT INTENDED TO BE A COMPLETE PERFORMANCE PRESENTATION OR ANALYSIS AND IS SUBJECT TO CHANGE. NONE OF ANABATIC INVESTMENT PARTNERS LLC, AS INVESTMENT MANAGER, THE FUNDS OR PRODUCTS REFERRED TO HEREIN OR ANY AFFILIATE, MANAGER, MEMBER, OFFICER, EMPLOYEE OR AGENT OR REPRESENTATIVE THEREOF MAKES ANY REPRESENTATION OR WARRANTY WITH RESPECT TO THE INFORMATION PROVIDED HEREIN. AN INVESTMENT IN ANY FUND OR PRODUCT REFERRED TO HEREIN IS SPECULATIVE AND INVOLVES A HIGH DEGREE OF RISK. THERE CAN BE NO ASSURANCE THAT THE INVESTMENT OBJECTIVE OF ANY SUCH FUND OR PRODUCT WILL BE ACHIEVED. MOREOVER, PAST PERFORMANCE SHOULD NOT BE CONSTRUED AS A GUARANTEE OR AN INDICATOR OF THE FUTURE PERFORMANCE OF ANY FUND OR PRODUCT. AN INVESTMENT IN ANY FUND OR PRODUCT REFERRED TO HEREIN CAN LOSE VALUE. INVESTORS SHOULD CONSULT THEIR OWN PROFESSIONAL ADVISORS AS TO LEGAL, TAX AND OTHER MATTERS RELATING TO AN INVESTMENT IN ANY FUND OR PRODUCT.

THIS IS NOT AN OFFER TO SELL OR SOLICITATION OF AN OFFER TO BUY AN INTEREST IN A FUND OR PRODUCT. ANY SUCH OFFER OR SOLICITATION WILL BE MADE ONLY BY MEANS OF DELIVERY OF A FINAL OFFERING MEMORANDUM, PROSPECTUS OR CIRCULAR RELATING TO SUCH FUND AND ONLY TO QUALIFIED INVESTORS IN THOSE JURISDICTIONS WHERE PERMITTED BY LAW.

ALL FUND OR PRODUCT PERFORMANCE, ATTRIBUTION AND EXPOSURE DATA, STATISTICS, METRICS OR RELATED INFORMATION REFERENCED HEREIN IS ESTIMATED AND APPROXIMATED. SUCH INFORMATION IS LIMITED AND UNAUDITED AND, ACCORDINGLY, DOES NOT PURPORT, NOR IS IT INTENDED, TO BE INDICATIVE OR A PREDICTOR OF ANY SUCH MEASURES IN ANY FUTURE PERIOD AND/OR UNDER DIFFERENT MARKET CONDITIONS. AS A RESULT, THE COMPOSITION, SIZE OF, AND RISKS INHERENT IN AN INVESTMENT IN A FUND OR PRODUCT REFERRED TO HEREIN MAY DIFFER SUBSTANTIALLY FROM THE INFORMATION SET FORTH, OR IMPLIED, HEREIN.

PERFORMANCE DATA IS PRESENTED NET OF APPLICABLE MANAGEMENT FEES AND INCENTIVE FEES/ALLOCATION AND EXPENSES, EXCEPT FOR ATTRIBUTION DATA, TO THE EXTENT REFERENCED HEREIN, OR AS MAY BE OTHERWISE NOTED HEREIN. NET RETURNS, WHERE PRESENTED HEREIN, ASSUME AN INVESTMENT IN THE APPLICABLE FUND OR PRODUCT FOR THE ENTIRE PERIOD REFERENCED. AN INVESTOR’S INDIVIDUAL PERFORMANCE WILL DIFFER BASED UPON, AMONG OTHER THINGS, THE FUND OR PRODUCT IN WHICH SUCH INVESTMENT IS MADE, THE INVESTOR’S “NEW ISSUE” ELIGIBILITY (IF APPLICABLE), AND DATE OF INVESTMENT. IN THE EVENT OF ANY DISCREPANCY BETWEEN THE INFORMATION CONTAINED HEREIN AND THE INFORMATION IN AN INVESTOR’S MONTHLY ACCOUNT STATEMENT IN RESPECT OF THE INVESTOR’S INVESTMENT IN A FUND OR PRODUCT REFERRED TO HEREIN, THE INFORMATION CONTAINED IN THE INVESTOR’S MONTHLY ACCOUNT STATEMENT SHALL GOVERN.

NOTE ON INDEX PERFORMANCE

INDEX PERFORMANCE DATA AND RELATED METRICS, TO THE EXTENT REFERENCED HEREIN, ARE PROVIDED FOR COMPARISON PURPOSES ONLY AND ARE BASED ON (OR DERIVED FROM) DATA PUBLISHED OR PROVIDED BY EXTERNAL SOURCES. THE INDICES, THEIR COMPOSITION AND RELATED DATA GENERALLY ARE OWNED BY AND ARE PROPRIETARY TO THE COMPILER OR PUBLISHER THEREOF. THE SOURCE OF AND AVAILABLE ADDITIONAL INFORMATION REGARDING ANY SUCH INDEX DATA IS AVAILABLE UPON REQUEST.

Por qué preferimos empresas con poca deuda

February 22, 2019 in Miscelánea, MOI Global en Español

NOTA DEL EDITOR: Este texto es obtenido de una carta trimestral a los inversores de Magallanes Value Investors.

* * *

En otro orden de cosas, recientemente asistí a una reunión de inversores con una empresa cuyo balance mostraba caja neta. Todo bien hasta que en el turno de preguntas alguien del grupo cuestionó la estructura de capital de la empresa, por ineficiente se entiende.

Acostumbrados a que los inversores preguntemos sobre planes estratégicos, operaciones corporativas, política de dividendos, etc.…la pregunta cogió por sorpresa al equipo directivo. Reconozco que a mí también, lo cual me hizo reflexionar sobre nuestra “obsesión” por empresas con poca deuda, o al menos que sea manejable, y preferiblemente caja neta, todo lo contrario, por otro lado, a lo que demandaba el inversor que formuló la pregunta.

Continue reading »

My Investment Thesis on Trupanion

February 21, 2019 in Ideas, Letters

This article is authored by MOI Global instructor Mark Walker, Managing Partner at Tollymore Investment Partners, based in London.

In December 2018 we acquired shares of Trupanion (TRUP) at a price of $23.3 per share. TRUP is a founder-led, simple one-product-one-geography business with single-minded focus on a niche service. TRUP has a superior value proposition and strong competitive position afforded by gestation of distributor relationships, a data flywheel and customer switching costs. It operates in a large addressable market with a significant penetration opportunity affording a potentially multi-decade runway for compounding owner earnings. It may come as a surprise that TRUP is also an insurance company.

TRUP provides medical insurance for cats and dogs in the US and Canada. The problem that Trupanion is trying to solve is that it is difficult for pet owners to budget for the magnitude and timing of pet illness and injury. Pet owners do not know the average costs of pet healthcare for the pets that they own. Even if they did, they would not know if their pets will be lucky or unlucky for that breed and location.

Trupanion’s solution is a cost-plus insurance product which spreads the risk that the customer’s pet is unlucky by subsidising unlucky pets with lucky pet premiums. Like any insurance product Trupanion allows customers to budget for the unpredictable timing and magnitude of loss, in this case pet healthcare costs.

The distribution of TRUP’s insurance products is primarily through vet and customer referrals. TRUP uses a network of c. 100 independent contractors called ‘Territory Partners’ to build long term relationships with vets; they are responsible for making vets aware of the benefits of TRUP’s products to the vet’s customers, with the goal of earning the trust of the vets.

Like any insurer, TRUP must estimate and hold reserves for vet invoices which have been incurred but not yet submitted, a complex process requiring subjective judgement. Unlike most insurers TRUP is a cash in – cash out business; it does not have a substantial float, nor does the investment income from that float contribute meaningfully to the business’s discretionary profits.

Given pet insurance penetration rates in the US of 1%, TRUP’s primary competitor is the pet owner who chooses to self-fund pet healthcare costs with cash or debt. TRUP is therefore focused on growing the addressable market vs. taking market share from existing players; the primary challenge in achieving this is the education of pet owners about the merits of TRUP’s pet insurance.

The nature of the insurance business model – risk is spread over a large membership for lucky pets to subsidise unlucky pets – is a barrier to profitable entry for small insurance providers. For example, given the fragmented nature of the vet industry, it would not be possible for individual vets to offer their customers insurance products.

TRUP is the largest player in Canada and the second largest in the US, behind Nationwide. Nationwide started in 1982 and was the first pet insurer in the US. It has c. 550k enrolled pets; TRUP has rapidly grown to c. 500k pets and it is likely that TRUP will become the largest player in the US soon.

High retention and net subscriber addition rates are evidence of a strong value proposition. The sources of this superior value proposition stem from (1) a cost advantage that is shared with customers, (2) a data advantage driving more accurate underwriting, and (3) switching costs and symbiotic value chain.

TRUP is vertically integrated; it owns its insurance subsidiary and is responsible for acquiring and servicing existing customers as well as underwriting their insurance. TRUP estimates this vertical integration has eliminated frictional costs of c. 20% of revenues. These economic savings have been donated to consumers in the form of higher claims payout ratios. TRUP’s strategy has therefore been to sacrifice the near-term margin upside of this cost advantage in the pursuit of a larger and stickier customer base and subscription revenue pool. This cost advantage does not manifest itself in lower prices, but rather the highest sustainable expenditure on vet invoices per dollar of premiums.

TRUP has built a database over 15 years using 7.5mn pet months of information and > 1mn claims; it has segmented the market into 1.2mn price categories in order to more accurately underwrite insurance costs for a given pet. Of course, determining the point at which the marginal returns on incremental data diminish is difficult, but according to the CEO it would take a competitor 13 years to replicate this data asset. Although Nationwide is larger by number of pets enrolled, its data are likely to be less comprehensive for two reasons: (1) a lack of data for conditions not covered by policies, such as hereditary and congenital diseases, and (2) pricing categories by state rather than zip code, even though the cost of vet care can vary widely within states. TRUP considers its ability to accurately estimate the costs of pet healthcare costs by granular sub- categories crucial to its leading value proposition. This allows for the provision of more relevant products for the customer.

Trupanion Express is software that was developed by TRUP and integrates with vets’ practice management systems. Through Trupanion Express, TRUP pays vets directly, within five minutes of a vet invoice being submitted, disrupting the traditional insurance reimbursement model and obviating the need for customers to pay out of pocket and then submit a claim for the expense. This is clearly a superior solution to the reimbursement model in solving customers’ cash flow problem associated with unexpected pet healthcare costs. In general, pet owners do not switch insurance providers due to the non-coverage of pre-existing conditions. Trupanion Express is installed in 10% of the 20k hospitals being visited by Territory Partners each year. The integration of this software is likely to improve the loyalty of pet owners and vets.

Finally, TRUP insurance seems to be a win-win-win proposition for pet owners, vets and TRUP:

  • Vets’ treatment decisions can be dictated by efficacy rather than cost. Pet owners visit the vet more frequently and are more likely to agree to the vet’s Plan A treatment recommendation. The goal for Territory Partners is to sign vets up to Trupanion Express, which is free, removes bad debt issues and therefore fosters better relationships with customers. Trupanion Express also eliminates credit card fees, which may constitute c.15% of a vet’s profits.
  • Pet owners have peace of mind that they will not be hit with unexpected large vet bills and are therefore also less likely to choose economic euthanasia or suboptimal treatment plans. With Trupanion Express they do not need to settle vet invoices out of pocket and then attempt to cover the claim through the traditional reimbursement model.
  • Through Trupanion Express TRUP improves the retention of its customer base, freeing up discretionary capital for accelerated pet acquisition.

The addressable market is large and underpenetrated relative to other developed markets. The differences in these other markets are not demographic, social or economic, but rather (1) the length of time comprehensive pet insurance has been available, (2) the value proposition in the form of higher claims payments as a ratio to premiums (higher loss ratios) and (3) vet vs. direct to consumer distribution models. Pet insurance companies in the US typically do not cover hereditary and congenital conditions, which are the forms of illness most likely to be suffered by cats and dogs, they increase rates when claims are made, they impose payout limits, and pay claims according to an estimated cost schedule rather than actual vet invoices. TRUP is different in all these respects and as such expects to grow the addressable market in North America to greater than 1% penetration. In any case, it appears to be the case that TRUP’s value proposition is driving adoption in North America.

The unit economics associated with the pursuit of this opportunity to grow the company’s assets are attractive. The cost to acquire a pet is c. $150, around 3x the average monthly ARPU. Assuming the current 10% discretionary margin and a six-year average pet life, the IRR on new pets is 30-40%. At a 15% discretionary margin the IRR would be double this. I estimate that both ARPUs and discretionary margins would need to decline by 20-25% to render reinvestment in pet acquisition a capital destructive pursuit. This would contradict the economic reality of a market in which pet healthcare costs are increasing mid-single digits as new technologies and treatments are ported over from human healthcare, and the scalability of the business model.

The CEO owns 7% of TRUP equity/$60mn and in total the executive leadership team owns 10%. This is c 100x the CEO’s annual compensation. He automatically sells 2% of his shares each year until he has sold 25% of his interest in the company by 2025. This has been a source of criticism from short sellers but given the large gap between stock ownership and annual remuneration, and the zero-dividend policy, I don’t think this represents misalignment with other minority owners of the business.

TRUP’s quoted market cap is c. $800mn, c.6x BV and 24x owner earnings of c. $33mn. A 4% owner earnings’ yield is reasonable for a business with TRUP’s high reinvestment rates and incremental returns on new capital investments if these can be successfully maintained. The strength of TRUP’s competitive position and evidence that their value proposition is attractive to pet owners suggest that they can. These owner earnings are one quarter of book value, and the company is growing its assets (enrolled pets) 20-30% each year; 6x BV implies a 6% sustainable growth rate.

Yet incremental returns on reinvested capital are higher than the return on existing net assets, leading to growth rates many multiples of that implied by the market. Finally, management expects scaling of the fixed cost base to drive margin expansion, leading to economic earnings growth higher than revenue growth. By 2020 if management achieves its targets it should be generating c. $450mn of revenues and $65-70mn of discretionary profits. Given the company expects to reinvest all discretionary profits into growing enrolled pets, retained losses are unlikely to improve over that time, leading to a potential RoE of c. 50% in 2020 on an owner earnings basis. At the current price the stock would then be trading at a multiple of its book value that implied zero growth, despite the ample room for enrolled pet expansion afforded by low market penetration and a leading value proposition.

Disclaimer: The contents of this document are communicated by, and the property of, Tollymore Investment Partners LLP. Tollymore Investment Partners LLP is an appointed representative of Eschler Asset Management LLP which is authorised and regulated by the Financial Conduct Authority (“FCA”). The information and opinions contained in this document are subject to updating and verification and may be subject to amendment. No representation, warranty, or undertaking, express or limited, is given as to the accuracy or completeness of the information or opinions contained in this document by Tollymore Investment Partners LLP or its directors. No liability is accepted by such persons for the accuracy or completeness of any information or opinions. As such, no reliance may be placed for any purpose on the information and opinions contained in this document. The information contained in this document is strictly confidential. The value of investments and any income generated may go down as well as up and is not guaranteed. Past performance is not necessarily a guide to future performance.

Enzo Biochem: Multiple Shots on Goal at Recent Price

February 19, 2019 in Equities, Ideas, Letters

This post is excerpted from a letter by MOI Global instructor Jim Roumell, partner and portfolio manager of Roumell Asset Management, based in Chevy Chase, Maryland.

Jim discussed Enzo Biochem in his talk at Best Ideas 2019.

ENZ is a debt-free company possessing a strategically located clinical lab footprint (NY Tri-State area) in a consolidating industry. Moreover, the company has significant IP assets, a therapeutics business we expect to be monetized in the first half of 2019, and considerable IP litigation optionality. ENZ’s market cap is roughly $160 million and it has $53 million in cash, which equates to an Enterprise Value of $107 million.

The company has won settlements/royalty payments of $100 million ($67 million net) over the past several years, highlighting its rich IP assets. ENZ’s current enterprise value is roughly 110% of what the company has collected in IP litigation. The company has seven outstanding IP suits, six of which are financed on a contingency basis with the law firm that has already won ENZ suits against Illumina, Thermo Fisher Scientific and Siemens.

ENZ has multiple shots on goal, i.e., ways to win. The company’s share price has dropped from over $10 two years ago to its current sub-$3/share price because of dramatically reduced reimbursement payments (Medicare and private pay insurers) for its clinical lab services business.

While there is near-term pain associated with the reimbursement issue effecting ENZ’s lab business, it is ultimately well positioned to be a winner with its low-cost Ampiprobe diagnostic panels that the company believes possess a 60% gross margin given that it’s integrating its own IP. We believe smaller, independent labs are being particularly squeezed by reimbursement payments and that ENZ offers an outsourced diagnostic solution.

On December 19th, we received indication that the litigation component of our investment thesis appears to be materializing when Enzo and Roche issued the following statement to the Honorable Denise L. Cote of the Southern District of New York; “Following up on the parties’ call to chambers yesterday, the parties are pleased to report that they have reached an agreement in principle to resolve the above-captioned matter. The parties are currently finalizing the agreement and related stipulation of dismissal and endeavoring to have those completed shortly after the new year,” further stipulating that a settlement would be reached by January 25, 2019. On January 24th, the parties made a request for a two-week extension to file settlement terms. Until then, we wait.

Disclosure: The specific securities identified and described do not represent all of the securities purchased, sold, or recommended for advisory clients, and the reader should not assume that investments in the securities identified and discussed were or will be profitable. The top three securities purchased in the quarter are based on the largest absolute dollar purchases made in the quarter.

MOI Global